Within the past 24 months, Mycoplasma fermentans, strain incognitus, has been linked with respiratory, central nervous system (CNS), and renal disease in AIDS patients. However, the incidence, natural history, pathogenic potential, and clinical significance of M. fermentans in AIDS patients is unknown. Furthermore, there have been no published attempts to determine if the occurrence of other mycoplasmas, several of which are proven pathogens, is increased in AIDS patients. Other mycoplasmas known to cause disease in humans include Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. The latter two are associated with urogenital diseases, but are also known opportunists, causing disseminated disease in hypogammaglobulinemic patients, those undergoing immunosuppressive therapy, and in premature infants. M. pneumoniae is a respiratory pathogen in all age groups accounting for up to 20% of all pneumonias and up to 50% in closed populations. There are several reasons that mycoplasmas may have been previously overlooked in AIDS patients. Mycoplasmas are fastidious and demanding in their requirements for special media and most hospital laboratories lack the capabilities to isolate them. Therefore, diagnosis is often based on exclusion or serological reactions. Without a high index of suspicion, they would not be included in a differential diagnosis and serological reactions may not be diagnostic in HIV-infected persons.
The specific aims of the present proposal are: (i) To determine the prevalence of mycoplasmal infections, specifically M. fermentans, M. pneumoniae, M. hominis, M. pirum, U. urealyticum, and M. genitalium in patients with various stages of HIV-1 infection compared to age, sex, and risk-matched non-HIV infected controls; and (ii) To determine if disseminated mycoplasmal infection in particular pneumonitis and central nervous system manifestations not due to other causes, occur in AIDS patients.

Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Lockman, Shahin; Hughes, Michael; Sawe, Fred et al. (2012) Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 9:e1001236
Ciaranello, Andrea L; Lockman, Shahin; Freedberg, Kenneth A et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25:479-92
Boltz, Valerie F; Zheng, Yu; Lockman, Shahin et al. (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 108:9202-7
Haas, David W; Koletar, Susan L; Laughlin, Laura et al. (2009) Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 50:290-3
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Twigg Iii, Homer L; Weiden, Michael; Valentine, Fred et al. (2008) Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 197:109-16
Kilby, J Michael; Lee, Ha Youn; Hazelwood, J Darren et al. (2008) Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 22:957-62
Riddler, Sharon A; Jiang, Hongyu; Tenorio, Allan et al. (2007) A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 12:531-41
Acosta, Edward P; Kendall, Michelle A; Gerber, John G et al. (2007) Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 51:3104-10

Showing the most recent 10 out of 71 publications